BRPI0509642A - composição oral de molsidomina de liberação prolongada para o tratamento de aterosclerose - Google Patents

composição oral de molsidomina de liberação prolongada para o tratamento de aterosclerose

Info

Publication number
BRPI0509642A
BRPI0509642A BRPI0509642-1A BRPI0509642A BRPI0509642A BR PI0509642 A BRPI0509642 A BR PI0509642A BR PI0509642 A BRPI0509642 A BR PI0509642A BR PI0509642 A BRPI0509642 A BR PI0509642A
Authority
BR
Brazil
Prior art keywords
molsidomine
atherosclerosis
release
treatment
prolonged
Prior art date
Application number
BRPI0509642-1A
Other languages
English (en)
Inventor
Jozsef-Michel Geczy
Original Assignee
Therabel Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Therabel Pharmaceuticals Ltd filed Critical Therabel Pharmaceuticals Ltd
Publication of BRPI0509642A publication Critical patent/BRPI0509642A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

COMPOSIçãO ORAL DE MOLSIDOMINA DE LIBERAçãO PROLONGADA PARA O TRATAMENTO DA ATEROSCLEROSE. A presente invenção encontra aplicação no domínio da indústria farmacêutica e tem como objeto o uso de molsidomina ou de um dos seus sais farmaceuticamente aceitáveis, particularmente sob a forma de uma composição oral sólida de liberação prolongada eficaz durante 24 horas, para a fabricação de um medicamento destinado a prevenir ou diminuir o desenvolvimento da aterosclerose.
BRPI0509642-1A 2004-04-05 2005-04-01 composição oral de molsidomina de liberação prolongada para o tratamento de aterosclerose BRPI0509642A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0403534A FR2868314B1 (fr) 2004-04-05 2004-04-05 Nouvelle utilisation therapeutique de la molsidomine et de ses sels pharmaceutiquement acceptables
PCT/EP2005/003531 WO2005107761A1 (fr) 2004-04-05 2005-04-01 Composition orale de la molsidomine a liberation prolongee pour le traitement de l’atherosclerose

Publications (1)

Publication Number Publication Date
BRPI0509642A true BRPI0509642A (pt) 2007-09-18

Family

ID=34944920

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0509642-1A BRPI0509642A (pt) 2004-04-05 2005-04-01 composição oral de molsidomina de liberação prolongada para o tratamento de aterosclerose

Country Status (29)

Country Link
US (1) US7754715B2 (pt)
EP (1) EP1732565B8 (pt)
JP (1) JP5117847B2 (pt)
KR (1) KR101162385B1 (pt)
CN (1) CN1938032B (pt)
AU (1) AU2005239799B2 (pt)
BE (1) BE1016580A3 (pt)
BR (1) BRPI0509642A (pt)
CA (1) CA2562287C (pt)
CY (1) CY1117614T1 (pt)
DK (1) DK1732565T3 (pt)
ES (1) ES2567576T3 (pt)
FR (1) FR2868314B1 (pt)
HK (1) HK1092736A1 (pt)
HR (1) HRP20160479T1 (pt)
HU (1) HUE029199T2 (pt)
IL (1) IL178440A0 (pt)
IT (1) ITTO20050220A1 (pt)
MA (1) MA28518B1 (pt)
MD (1) MD4080C1 (pt)
NO (1) NO336913B1 (pt)
NZ (1) NZ550341A (pt)
PL (1) PL1732565T3 (pt)
RS (1) RS54791B1 (pt)
RU (1) RU2388475C2 (pt)
SI (1) SI1732565T1 (pt)
UA (1) UA88461C2 (pt)
WO (1) WO2005107761A1 (pt)
ZA (1) ZA200608219B (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2668947T3 (pl) * 2012-05-31 2017-06-30 G. Pohl-Boskamp Gmbh & Co. Kg Indukcja arteriogenezy donorem NO, takim jak nitrogliceryna

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5385937A (en) * 1991-04-10 1995-01-31 Brigham & Women's Hospital Nitrosation of homocysteine as a method for treating homocysteinemia
FR2805462B1 (fr) * 2000-02-24 2003-08-15 Therabel Res Nouvelle forme galenique orale a liberation prolongee de la molsidomine
US6472390B1 (en) * 2001-11-13 2002-10-29 Duke University Use of therapeutic dosages for nitric oxide donors which do not significantly lower blood pressure or pulmonary artery pressure
KR100464876B1 (ko) * 2001-11-15 2005-01-06 학교법인 인제학원 동충하초의 코르디세핀을 함유하는 항혈전제 조성물
WO2010062256A1 (en) * 2008-11-27 2010-06-03 Nanyang Polytechnic Process and system for automatic identification of the larvae of aedes albopictus and aedes aegypti

Also Published As

Publication number Publication date
IL178440A0 (en) 2007-02-11
HK1092736A1 (zh) 2007-02-16
KR20070015534A (ko) 2007-02-05
ES2567576T3 (es) 2016-04-25
EP1732565B1 (fr) 2016-03-09
FR2868314A1 (fr) 2005-10-07
SI1732565T1 (sl) 2016-06-30
NO336913B1 (no) 2015-11-23
FR2868314B1 (fr) 2008-10-24
BE1016580A3 (fr) 2007-02-06
RU2006134695A (ru) 2008-05-20
UA88461C2 (ru) 2009-10-26
DK1732565T3 (en) 2016-05-09
KR101162385B1 (ko) 2012-07-06
HRP20160479T1 (hr) 2016-06-03
PL1732565T3 (pl) 2016-08-31
US20070212413A1 (en) 2007-09-13
MD4080B1 (en) 2010-12-31
AU2005239799A1 (en) 2005-11-17
HUE029199T2 (en) 2017-03-28
NZ550341A (en) 2009-11-27
RU2388475C2 (ru) 2010-05-10
MA28518B1 (fr) 2007-04-03
CA2562287C (fr) 2013-05-14
JP5117847B2 (ja) 2013-01-16
ZA200608219B (en) 2008-02-27
WO2005107761A1 (fr) 2005-11-17
EP1732565A1 (fr) 2006-12-20
CA2562287A1 (fr) 2005-11-17
AU2005239799B2 (en) 2010-12-23
CY1117614T1 (el) 2017-04-26
NO20064510L (no) 2006-10-31
CN1938032A (zh) 2007-03-28
US7754715B2 (en) 2010-07-13
RS54791B1 (sr) 2016-10-31
ITTO20050220A1 (it) 2005-10-06
JP2007531781A (ja) 2007-11-08
MD4080C1 (ro) 2011-07-31
CN1938032B (zh) 2010-06-09
EP1732565B8 (fr) 2016-05-11

Similar Documents

Publication Publication Date Title
BRPI0507966A (pt) uso de meloxicam para o tratamento de doenças respiratórias em porcos
TW200728285A (en) Diacylindazole derivatives as inhibitors of lipases and phospholipases
EE200300312A (et) Kinuklidiini derivaat, selle saamine ja kasutamine ravimi valmistamiseks, mis on ette nähtud respiratoorsete, kuseelundite või mao-soolte haiguste ravimiseks, ning seda sisaldav ravimkompositsioon
BR0202375A (pt) Composições farmacêutica compreendendo drogas e polìmeros de aumento da concentração
BRPI0508596A (pt) combinação compreendendo ligante alfa-2-delta
BRPI0518266B8 (pt) medicamento oral de liberação modificada de pelo menos um princípio ativo sob a forma multimicrocapsular
ATE540680T1 (de) Pharmazeutische aripiprazol-zusammensetzungen
MX2009004017A (es) Usos de los compuestos carboxi-amido triazol y sus sales.
BR0312165A (pt) Utilização da taurina para o tratamento da alopecia
BR112015029401A2 (pt) derivados pirazolo-pirrolidin-4-ona e seu uso no tratamento de doenças
ECSP088763A (es) Nuevas combinaciones terapéuticas para el tratamiento de la depresión
JP2006508953A5 (pt)
ATE505203T1 (de) Pharmazeutische kombination aus aliskiren und valsartan
EA200702282A1 (ru) Комбинация феррохина и производного артемизинина для лечения малярии
DE502006007702D1 (de) Tablettenförmige retardzubereitung enthaltend cinnarizin und dimenhydrinat gegen schwindel
BRPI0816798A2 (pt) composto, composição farmacêutica, métodos para inibir a ação do glicogênio sintase cinase-3, e para tratar, prevenir ou melhorar uma doença, uso de um composto, e, artigo de fabricação
BRPI0212298B8 (pt) composição farmacêutica compreendendo gabapentina ou um análogo da mesma e (alfa)-aminoamida e seu uso analgésico
CY1115384T1 (el) Αντι-φλεγμονωδης συνθεση
ATE541567T1 (de) Pharmazeutische zusammensetzung zur prävention und behandlung von metabolischen knochenerkrankungen mit alpha-arylmethoxyacrylat- derivaten
BRPI0818267A2 (pt) Novos derivados de 1,3-dihidro-5-isobenzofuranocarbonitrila e composição farmacêutica dos mesmos para o tratamento de ejaculação precoce
BRPI0703970A2 (pt) tratamento de pacientes psiquiátricos com função hepática reduzida com paliperidona
EA200801614A1 (ru) Фармацевтическая композиция, содержащая монтелукаст
DE602005025767D1 (de) Orale tedisamilformulierungen mit magenretentionseigenschaften und verzögerter freisetzung
RS54185B1 (en) USE OF 24-ORDER
BRPI0412364A (pt) composição farmacêutica sólida, compreendendo amisulpride

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL